Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression
Anjali Barnwal, Rohini Tamang, Sanjeev Das, Jayanta Bhattacharyya
Topics & Concepts
PonatinibCancer researchFOXP3Immune systemCD8BiologyPD-L1Immune checkpointTumor microenvironmentMAPK/ERK pathwayImmunotherapyImmunologyDasatinibKinaseCell biologyImatinibMyeloid leukemiaCancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismImmune cells in cancer